Sihuan Pharmaceutical (0460) Won the Fifth "Listed Enterprises of the Year 2020" Presented by Bloomberg Businessweek/Chinese Edition

Sihuan Pharmaceutical (0460) Won the Fifth "Listed Enterprises of the Year 2020" Presented by Bloomberg Businessweek/Chinese Edition

HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Bloomberg Businessweek/Chinese Edition announced that Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) won the fifth "Listed Enterprises of the Year 2020". The event received enthusiastic support with enterprises from a wide range of industries participated. Winners hail from such varied sectors as property development, transportation, information technology, industrials, entertainment, financing, and pharmaceuticals and biotechnology.

As a leading business magazine in the Greater China region, the Chinese Edition of Bloomberg Businessweek is proud to present the fifth "Listed Enterprises of the Year 2020", which aims to encourage listed enterprises with excellent performance and recognize their contribution to Hong Kong's economy. Winners must first pass the selection by Bloomberg Terminal based on business/financial performance, corporate governance, investor relationship, development strategy, corporate social responsibility, sustainability, innovation and risk management and then be assessed by a panel of ten judges from Governmental Organizations, Academics, and Professional bodies. The strength and development potential of the awardees are widely recognized among professionals and investors. Sihuan Pharmaceutical has successfully stood out among many listed companies and is well deserved to be the winner.

Sihuan Pharmaceutical, founded in 2001 and listed on the Main board of Hong Kong in 2010, is a group pharmaceutical enterprise integrating research, development, production and sales. It is one of the largest suppliers of cardio-cerebral vascular prescription drugs in China. Since 2012, Sihuan Pharmaceutical has continuously increased R&D investment every year, transition to product innovation and R&D, focusing on high-growth therapeutic areas with policy dividends such as tumor, diabetes, medical aesthetics, and cardio-cerebrovascular. After more than ten years of efforts, Sihuan Pharmaceutical has successfully built four industry-leading core business platforms:

Xuanzhu Biopharmaceutical Limited (here in after referred to as "Xuanzhu Biopharm"), Sihuan Pharmaceutical's independent research and development platform for innovative drugs, is a leading international innovative drug R&D enterprise which integrating independent R&D, clinical development, manufacturing and marketing of innovative drugs in China. Xuanzhu Biopharm focuses on major therapeutic areas such as oncology, metabolic diseases, and non-alcoholic hepatitis. There are total of 14 innovative projects under research, with complete independent intellectual property rights. The core first-class innovative drug products, Birociclib, a CDK4/6 inhibitor for advanced breast cancer has entered clinical phase II; A new generation of self-developed drugs for digestive diseases, Anaprozole sodium has entered clinical phase III. Xuanzhu Biopharm has a strong R&D strength and a world-class team of top scientists, and 175 clinical R&D professionals, many of whom returned from overseas with rich experience in the field of innovative drug R&D. Xuanzhu Biopharm has completed the first round of RMB800 million financing in this year, with a post-money valuation of RMB4.3 billion.

Jilin Huisheng Biological, a biological drug research and development platform with first-class drug research and development strength under Sihuan Pharmaceutical, was spun off in 2019 to create a leading biopharmaceutical company with full coverage in the field of diabetes and its complications treatment. 13 biological drugs among the products under research have huge market potential, including the fourth generation long-acting Insulin Degludec, which has entered the clinical III phase, and the research and development progress ranks first in China. In addition, the Company independently developed a Class 1 new drug SGLT-2 inhibitor (Janagliflozin tablet), which has completed the phase III clinical study and is about to submit for production. While developing a single drug for the treatment of diabetes, the company is also building a comprehensive product platform in the field of diabetes treatment by developing combination drug therapy, including metformin, DPP-4 inhibitors, GLP-1 analogues and so on.

In addition, the medical aesthetic platform of Sihuan Pharmaceutical is becoming a boost to the company's development. Sihuan Pharmaceutical started business in the medical aesthetic market in 2014, and signed an exclusive agency agreement with Hugel, a leading manufacturer of medical aesthetic products from South Korea, to jointly develop the Chinese market for its botulinum toxin and hyaluronic acid products. After six years of registration, the blockbuster botulinum toxin Letybo 100U was officially approved for sale in China in October, making it the fourth type A botulinum toxin product and the first of its kind from South Korea to be approved for sale in China. Because of this, Sihuan Medical Aesthetic becomes the leading medical aesthetic company in China's Market. In addition to the high- value products approved for sale, the core products, such as hyaluronic acid (Sihuan is the exclusive agent of Hugel from South Korea) and PLLA (independently developed), are also in the stage of registration and clinical development respectively. Sihuan Medical Aesthetic has built a strong marketing team, most of the team members are from Allergan, Inc. and other well-known foreign medical aesthetic enterprises. At present, the business has covered more than 200 cities, cooperation agencies reached more than 800. Sihuan Medical Aesthetic is determined to become an international medical aesthetic enterprise with a full product line.

Sihuan Pharmaceutical, meanwhile, already has China's leading platform for generic drug development, production and distribution, making it a strong cash cow for the Company. The platform contains 53 generic drugs with high technical barriers in the pipeline, which will be launched in the next 2-3 years, bringing continuous guarantee for the company's revenue and cash growth. PharmaDax (FoShan) Co., Ltd. (located in Foshan, Guangdong), a subsidiary of the Group, is an American GMP pharmaceutical production certification company, and its drugs have been exported to the United States. The Group has carried out shareholding conversion work, and will take control of the company and subsequently strengthen cooperation with Indian companies to create a generic drug export platform. Sihuan Pharmaceutical has a strong sales force of nearly 1,000 people, working closely with more than 3,000 distributors covering about 7,000 secondary and tertiary hospitals, with a distribution network covering 100% of the provinces. The new products of Company will have strong liquidity.

Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group said, "We are deeply honored, also deeply responsible and pressured to win the Listed Enterprises of the Year award. Sihuan Pharmaceutical's subsidiaries have been working together at all levels to promote the transformation of Sihuan Pharmaceutical from a traditional pharmaceutical company to a comprehensive pharmaceutical enterprise with a new international pattern. Sihuan Pharmaceutical will continue to center on patients, by providing them with a wider-range and better quality treatment options, analyzing the market development direction with depth, grasping market trends and opportunities, and focusing on new business growth points to form the most competitive, international, and professional pharmaceutical group enterprise."

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. ("Sihuan Pharmaceutical" or the "Company"), together with its subsidiaries (the "Group") is a pharmaceutical group with integrated research and development ("R&D"), production and marketing and sales capabilities. It is one of the largest suppliers of cardio-cerebral vascular ("CCV") prescription drugs in China. Sihuan Pharmaceutical has an excellent and professional marketing model, a nationwide distribution network, a diversified product portfolio with great market potential, as well as strong R&D capability. The Group continues to increase investment in R&D every year. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects. More than 300 patents on innovative drugs have been granted and over 80 of them are overseas patent. The Group's current pipeline projects cover key therapeutic areas including diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis, etc.

For more information about Sihuan Pharmaceutical, please visit the company website https://www.sihuanpharm.com/.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.